ETFs Lonza Group AG

LONN

CH0013841017

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 02:58:40 16/01/2026 pm IST			5-day change	1st Jan Change
562.60 ^CHF	-0.28%		+1.73%	+4.72%

14/01	Lonza Group AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
18/12	Swiss trade surplus at CHF 3.841 bln in November	RE

ETFs positioned on Lonza Group AG

Name	Varia. Jan 1.	Weight	AuM
LYXOR DJ SWITZERLAND TITANS 30 (DR) UCITS ETF- CHF	-.--%	3.83%	121 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	+1.50%	1.77%	26 M€
UBS (IRL) ETF PLC MSCI EUROPE ESG UNIVERSAL LOW CARBON SELECT UCITS ETF - ACC - EUR	-.--%	0.51%	0 M€
AMUNDI INDEX MSCI WORLD SRI PAB - UCITS ETF DR - HEDGED EUR (C)	-.--%	0.37%	0 M€
AMUNDI INDEX MSCI WORLD SRI PAB - UCITS ETF DR (C) - EUR	-.--%	0.37%	0 M€
VANECK MULTI-ASSET GROWTH ALLOCATION UCITS ETF - EUR	+1.88%	0.34%	31 M€
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	+2.96%	0.33%	32 M€
VANECK WORLD EQUAL WEIGHT SCREENED UCITS ETF - EUR	+4.07%	0.32%	1,101 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	+4.14%	0.18%	33,076 M€
VANECK MULTI-ASSET CONSERVATIVE ALLOCATION UCITS ETF - EUR	+2.90%	0.13%	20 M€
INDEXIQ FACTORS SUSTAINABLE EUROPE EQUITY UCITS ETF - EUR	+0.70%	0.12%	154 M€
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	-.--%	0.1%	0 M€
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB - UCITS ETF DR (C) - USD	-.--%	0.09%	0 M€
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	-.--%	0.09%	0 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	+3.26%	0.08%	386 M€
AMUNDI INDEX MSCI WORLD - UCITS ETF DR (C) - EUR	-.--%	0.07%	0 M€
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	-.--%	0.07%	0 M€
LEVERAGE SHARES PLC - 3X LONG TOTAL WORLD ETP	-.--%	0.07%	1 M€
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	+2.64%	0.05%	62 M€

1 2

Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (57.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (16.5%). In addition, the group offers nutritional ingredients; - small molecule drug substances (15.3%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (10.8%).

Employees

19,299

Sector

Biotechnology & Medical Research

Calendar

28/01 - Q4 2025 Earnings Release

More about the company